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Abstract: The present investigation evaluates the cardiovascular effects of the anorexigenic mediator
alpha-melanocyte stimulating hormone (MSH), in a rat model of type 2 diabetes. Osmotic mini pumps
delivering MSH or vehicle, for 6 weeks, were surgically implanted in Zucker Diabetic Fatty (ZDF)
rats. Serum parameters, blood pressure, and weight gain were monitored along with oral glucose
tolerance (OGTT). Echocardiography was conducted and, following sacrifice, the effects of treatment
on ischemia/reperfusion cardiac injury were assessed using the isolated working heart method.
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was measured to evaluate
levels of oxidative stress, and force measurements were performed on isolated cardiomyocytes to
determine calcium sensitivity, active tension and myofilament co-operation. Vascular status was also
evaluated on isolated arterioles using a contractile force measurement setup. The echocardiographic
parameters ejection fraction (EF), fractional shortening (FS), isovolumetric relaxation time (IVRT),
mitral annular plane systolic excursion (MAPSE), and Tei-index were significantly better in the
MSH-treated group compared to ZDF controls. Isolated working heart aortic and coronary flow was
increased in treated rats, and higher Hill coefficient indicated better myofilament co-operation in the
MSH-treated group. We conclude that MSH improves global heart functions in ZDF rats, but these
effects are not related to the vascular status.
Keywords: alpha-melanocyte-stimulating hormone; echocardiography; isolated working heart;
myocyte force; NADPH oxidase
1. Introduction
Diabetes mellitus type 2 (T2DM) is a long term, life-threatening metabolic disorder characterized
by high systemic glucose levels, insulin resistance and damage to many tissues due to dysregulated
inflammation [1–3]. Unfortunately for those afflicted, this disease persists for a lifetime and
progressively causes a wide range of debilitating effects, prominently: retinopathy, nephropathy,
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myocardial infarction, stroke, and damage to extremities severe enough to require amputation [4,5].
Pharmacotherapy for T2DM includes insulin analogues, biguanids, sulfonylureas, α-glucosidase
inhibitors, thiazolidinediones, SGLT-2-inhibitors, GLP-1 analogues, DPP-4-inhibitors, amylin
analogues. These agents may partly normalize blood glucose levels and attenuate the severe
downstream consequences, allowing management of the disease to some degree in many patients.
These therapeutic strategies are nevertheless palliative and generally fail to restore type 2 diabetics to
full health. Moreover, epidemiological studies show that incidence of this disorder has dramatically
increased to epidemic proportions [6–9]. Numerous factors have contributed to this phenomenon,
principally caused by sedentary lifestyle-related factors such as over-nutrition, lack of exercise and
particularly obesity [10–12]. Efforts to develop countermeasures to onset and pathogenesis of T2DM,
have focused particularly on physiological energy utilization mechanisms. Within this domain, the
melanocortin system plays a crucial role regulating whole body energy homeostasis since it functions
as a potent anorexigenic influence by controlling appetite resulting in lower food intake [13,14].
A major bioactive molecule in this system, adrenocorticotropic hormone (ACTH) is a peptide derived
from pro-opiomelanocortin (POMC). The first 13 amino acids of ACTH (ACTH 1-13) interact with
melanocortin receptors MCR1-MCR5 to produce biological effects [15–17].
Melanocortins are one of the most important regulators of human food intake behaviour
and thus strongly influence development of obesity, with resulting increased risk of T2DM
onset or exacerbation. It has also been shown that both peripheral and central injection of
melanocortin analogue caused a dramatic alteration in food intake and body weight [18–22].
Furthermore, genetic studies have revealed that mutations in genes coding for components of the
melanocortin system correlate with obesity and occurrence of T2DM in both animals and humans [23].
Mechanistic studies reveal that alpha-MSH activates the MC5R signalling pathway via cyclic adenosine
monophosphate/protein kinase A (cAMP/PKA) and mitogen-activated protein kinase/extracellular
signal-regulated (MAPK/ERK1/2) and significantly decreases the fat content of adipocytes [24–26].
In addition to these effects, the beneficial properties of α-MSH have been characterized in many other
animal disease models, in which this system exhibits antiapoptotic, anti-inflammatory, antiischemic,
antioxidant features [27–30]. Nevertheless, greater insight into the fact how these molecules may
affect cardiomyocyte force during long-term treatment regimens would clearly be beneficial [31–34].
The present investigation addresses this gap in understanding of cellular processes underlying
functions of the melanocortin system. This preclinical study was designed to demonstrate effects
of alpha-MSH stimulation sustained over a fairly long time period (6 weeks) on cardio metabolic
parameters, diastolic cardiac function, and myofilament co-operation using an osmotic mini pump
in the Zucker diabetic fatty rat model. The major objective of the study is to characterize the
adaptive/protective role of this peptide on metabolic, cardiac or vascular status of diabetic tissues.
2. Results
2.1. Weight Gain, Serum Parameters, Blood Pressure and LV Mass/Whole Body Mass Ratio
Initial body weight of animals was 326.70 ± 5.723 g. Weight gain of the animals by treatment
groups, serum cholesterol and triglyceride values and results of non-invasive blood pressure
measurements are shown in Table 1. No significant differences were found in the abovementioned
parameters. On the contrary, significant change was observable between the control and alpha-MSH
treated groups in the ratio of left ventricle (LV) mass to whole body mass at the endpoint (Table 1).
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Table 1. Weight, weight gain, left ventricle (LV) mass and body weight ratio (measured by
echocardiography), serum parameters and blood pressure results of untreated control (n = 6) and
alpha-MSH-treated (n = 6) Zucker Diabetic Fatty (ZDF) rats. No significant changes were found in
weight gain, plasma cholesterol and triglyceride and blood pressure values among groups. Even though
decreased LV mass to body weight ratios were measured in the melanocyte stimulating hormone (MSH)
group at the endpoint when compared to Control. * vs. Control, p < 0.05, Student’s t-test.
Parameter Control MSH
Endpoint weight (g) 358.7 ± 7.154 391.8 ± 17.00
Weight gain (%) 20.23 ± 2.444 17.65 ± 2.225
Baseline LV mass/Baseline bodyweight (%) 0.337 ± 0.011 0.321 ± 0.017
Endpoint LV mass/Endpoint bodyweight (%) 0.320 ± 0.011 0.2770 ± 0.010 *
Total cholesterol (mmol/L) 3.445 ± 0.210 3.295 ± 0.074
HDL (mmol/L) 2.082 ± 0.194 1.768 ± 0.092
Triglyceride (mmol/L) 3.487 ± 0.318 3.068 ± 0.344
Systolic BP (mmHg) 134.00 ± 4.073 142.2 ± 1.900
Diastolic BP (mmHg) 96.25 ± 3.484 105.5 ± 4.400
2.2. Results of OGT Tests
Results of Oral Glucose Tolerance Test (OGTT) are shown on Figure 1. Values of ZDF control and
alpha-MSH-treated animals were elevated compared to the baseline (BASE), but no significant changes
were observed in MSH group compared to Control at any time points.
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Figure 1. Results of the Oral Glucose Tolerance Test (OGTT) carried out at the start and on the 6th week
of the experiment. No significant differences were seen between alpha-MSH-treated and untreated
ZDF animal-groups. One-way ANOVA, all data is presented as mean ± SEM. * vs. BASE, p < 0.05.
2.3. Echocardiography
Outcomes of echocardiographic analyses at the start and enpoint are shown in Table 2.
Systolic parameters (EF, FS, MAPSE) and diastolic values (E wave velocities, E/e’ ratio, and IVRT) were
found to be deteriorated in ZDF Control group compared to baseline (BASE) data (see Table 2). Mild but
significant increase in Tei-index (0.491± 0.014 vs. 0.305± 0.012) shows worsened global heart function.
Systolic function of MSH group animals showed a mild improvement in comparison to Control group,
demonstrated by fractional shortening (FS), ejection fraction (EF) and mitral annular plane systolic
excursion (MAPSE) parameters. FS and EF of alpha-MSH-treated animals were significantly increased
in comparison with values of ZDF control animals (FS: 32.33 ± 0.421% vs. 36.83 ± 0.703%; and EF:
66.50 ± 0.067% vs. 72.00 ± 0.774%, respectively). MAPSE values of SH rats were maintained
at the normal range [35,36], however, MAPSE was significantly deteriorated in ZDF control rats
(2.268 ± 0.010 mm vs. 1.602 ± 0.045 mm). Diastolic function of the left ventricle was slightly improved
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in alpha-MSH-treated animals compared to ZDF Controls, demonstrated by a decrease in isovolumic
relaxation time (58.00 ± 1.826 ms vs. 43.00 ± 1.125 ms). Diameter of the left atrium was increased in
ZDF controls compared to MSH animals showed by left atrium to aortic (LA/Ao) ratios (1.104 ± 0.043
vs. 0.945 ± 0.029). E/A and E/e’ ratios, as well as lateral e’ parameters were found to be unaffected by
the treatment. Tei index (Myocardial Performance Index, MPI) was elevated in Control animals when
compared to MSH group, showing deteriorated global heart function in Control rats (0.491 ± 0.014
vs. 0.392 ± 0.013). Left ventricle outflow tract (LVOT) parameters were also found to be significantly
increased in MSH group compared to ZDF Controls. Alpha-MSH treatment slightly elevates blood
flow velocities (V) and pressure gradient (PG) (LVOTV mean: 0.441 ± 0.024 m/s vs. 0.553 ± 0.019 m/s;
and LVOT mean PG: 1.095 ± 0.088 mmHg vs. 1.592 ± 0.106 mmHg). Consequently, stroke volume
(SV) and cardiac output (CO) were found to be elevated in treated animals (SV: 0.406 ± 0.046 mL vs.
0.581 ± 0.030 mL; and CO: 77.55 ± 7.763 mL/min vs. 112.30 ± 6.110 mL/min, respectively). Heart
rate values did not show any difference among groups when measured on anaesthetized animals
by echocardiography.
Table 2. Echocardiographic parameters of untreated control and alpha-MSH-treated ZDF rats at the
baseline and at the endpoint of the study. Ejection fraction (EF), fractional shortening (FS), stroke
volume (SV), cardiac output (CO) and mitral plane systolic excursion (MAPSE) were elevated in
treated group. Isovolumic relaxation time (IVRT) and isovolumic contraction time (IVCT) were
lengthened in ZDF animals, but shortened in alpha-MSH-treated group. Myocardial Performance
Index (MPI or Tei-index) and left atrium to aortic ratio (LA/Ao) were also improved after the treatment.
One-way ANOVA was used to estimate statistical differences. v vs. BASE, p < 0.05; * vs. Control,
p < 0.05.
Parameter BASE Control MSH
LA/Ao ratio 1.133 ± 0.039 1.104 ± 0.043 0.945 ± 0.029 *
LV Ejection Fraction (%) 73.17 ± 1.973 66.50 ± 0.067 v 72.00 ± 0.774 *
LV Fractional Shortening (%) 37.50 ± 1.500 32.33 ± 0.421 v 36.83 ± 0.703 *
IVSd (mm) 1.845 ± 0.164 1.550 ± 0.044 1.613 ± 0.099
LVIDd (mm) 7.038 ± 0.048 7.747 ± 0.328 7.688 ± 0.248
IVSs (mm) 2.603 ± 0.075 2.143 ± 0.093 v 2.097 ± 0.103
LVIDs (mm) 4.385 ± 0.103 5.232 ± 0.226 4.858 ± 0.117
Stroke volume (mL) 0.428 ± 0.037 0.406 ± 0.046 0.581 ± 0.030 *
Cardiac Output (mL/min) 99.89 ± 8.236 77.55 ± 7.763 112.30 ± 6.110 *
HR (bpm) 235.8 ± 8.462 192.7 ± 4.185 v 193.3 ± 6.259 v
LVOT maxPG (mmHg) 3.173 ± 0.217 2.698 ± 0.254 3.765 ± 0.284 *
LVOT meanPG (mmHg) 1.178 ± 0.138 1.095 ± 0.088 1.592 ± 0.106 *
LVOT Vmax (m/s) 0.887 ± 0.029 0.818 ± 0.038 0.965 ± 0.036 *
LVOT Vmean (m/s) 0.447 ± 0.032 0.441 ± 0.024 0.553 ± 0.019 *
Lateral e’ (mm/s) 39.50 ± 1.803 26.83 ± 1.939 v 28.33 ± 0.614
MV E velocity (m/s) 0.887 ± 0.025 0.743 ± 0.014 v 0.710 ± 0.027
MV A velocity (m/s) 0.477 ± 0.027 0.438 ± 0.022 0.403 ± 0.018
MV E/A ratio 1.885 ± 0.109 1.802 ± 0.048 1.770 ± 0.101
MV Deceleration Time (ms) 55.67 ± 3.333 66.67 ± 3.201 85.50 ± 5.258 *
E/e’ ratio 22.59 ± 0.832 28.47 ± 2.220 v 25.11 ± 1.070
MAPSE (mm) 2.167 ± 0.061 1.602 ± 0.045 v 2.268 ± 0.010 *
Ejection Time (ms) 100.7 ± 2.459 83.17 ± 2.926 v 93.17 ± 3.877
IVCT (ms) 18.50 ± 1.708 23.50 ± 1.727 17.83 ± 0.703 *
IVRT (ms) 25.00 ± 1.390 58.00 ± 1.826 v 43.00 ± 1.125 *
MPI (Tei-index) 0.305 ± 0.012 0.491 ± 0.014 v 0.392 ± 0.013 *
2.4. Isolated Working Heart Results
The impact of MSH on the ischemic heart was measured by working heart apparatus after 6 weeks
following surgery. Six weeks of treatment had no effect on pre-ischemic parameters of contractile
function including aortic flow, coronary flow, heart rate, cardiac output, stroke volume and aortic
pressure in hearts isolated from either Control or MSH-treated rats (Figure 2).
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Figure 2. Results of the isolated working heart method. (A) aortic flow values; (B) coronary flow
values; (C) heart rate values; (D) cardiac output values; (E) stroke volume values; (F) aortic pressure
values; (G) dp/dt values; (H) aortic flow 30 min after reperfusion; (I) stroke volume 30 min after
reperfusion; (J) pre-ischemic dp/dt values; (K) dp/dt 60 min after reperfusion; (L) dp/dt 120 min
after reperfusion. One-way ANOVA was used (Figure 2A–G), all data is presented as mean ± SEM.
* p < 0.05 compared to pre-ischemic Control values. v p < 0.05 compared to pre-ischemic MSH treated
values. * p < 0.05 compared to control values at the same time point during isolated working heart
experiments (Student’s t-test, Figure 2H–L).
However, although nearly all parameters showed no differences in pre-ischemic state, in time
derivative of developed pressure MSH group featured significantly lower compared to Control
group (Figure 2H). Interestingly, in 60 and 120 min of recovery the dp/dt was significantly higher in
MSH group than Control parameters in the same time points (Figure 2K,L). Furthermore, 30 min after
global ischemia AF and SV were increased in MSH group compared to Control (Figure 2I,J). In addition,
at the end of post-ischemic recovery, AF (1.667 ± 0.711; Figure 2A), CO (11.500 ± 3.708; Figure 2D),
SV (0.072± 0.024; Figure 2E), AoP (40.500± 12.230; Figure 2F) and dp/dt (341.700± 71.830; Figure 2G)
were significantly suppressed in hearts isolated from Control rats compared to their pre-ischemic state
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(AFpre: 23.170 ± 4.554; COpre: 43.500 ± 5.054; dp/dtpre : 1650 ± 96.120; AoPpre: 93.330 ± 9.482 and
SVpre: 0.268 ± 0.021). In contrast, only the post-ischemic AF (2.400 ± 0.778), AoP (68.800 ± 3.952)
and dp/dt (558.300 ± 55.630) showed significant reduction in MSH treated group compared to
pre-ischemic values (AFpre: 22.800 ± 2.480; dp/dtpre: 1133 ± 127.200; AoPpre: 98.200 ± 2.760).
In other words, despite the fact that there were few remarkable differences between the two groups
at parallel time points of measurement, in MSH group post-ischemic CO (19.400 ± 2.849) and
SV (0.128 ± 0.025) values did not reach statistical significance in reduction compared to their
pre-ischemic state (COpre: 42.000 ± 4.195; SVpre: 0.249 ± 0.021). No significance was found in
coronary flow and heart rate values, neither between groups, nor between different time points of the
same group (Figure 2B,C).
2.5. Enhancement of Cardiomyocyte Contractile Performance after Alpha-MSH Treatment
Active tension-pCa relationships of LV cardiomyocytes (Figure 3A) apparently showed
alpha-MSH-induced changes in cellular mechanical performance of ZDF rats. LV cardiomyocytes from
ZDF animals after vs. without alpha-MSH treatment had a trend towards higher active tension (at
pCa 5.6: 31.04 ± 3.44 kN/m2 vs. 23.38 ± 2.46 kN/m2, p = 0.08; at pCa 5.8: 25.50 ± 3.43 kN/m2 vs.
18.13 ± 2.15 kN/m2, p = 0.08). Normalized force-pCa relationships of LV cardiomyocytes (Figure 3B)
from treated vs. Control ZDF rats showed similar Ca2+ sensitivity (pCa50: 5.87 ± 0.03 vs. 5.82 ± 0.02;
Figure 3C), but significantly higher Hill coefficient (nHill: 2.87 ± 0.19 vs. 2.17 ± 0.08; Figure 3D) as
indicative for better myofilament co-operation in the alpha-MSH-treated group.
Molecules 2017, 22, 1702 6 of 18 
 
group (Figure 2H). Interestingly, in 60 and 120 min of recovery the dp/dt was significantly higher in 
MSH group than Control parameters in the same time points (Figure 2K,L). Furthermore, 30 min 
after global ischemia AF and SV were increased in MSH group compared to Control (Figure 2I,J). In 
addition, at the end of post-ischemic recovery, AF (1.667 ± 0.711; Figure 2A), CO (11.500 ± 3.708; 
Figure 2D), SV (0.072 ± 0.024; Figure 2E), AoP (40.500 ± 12.230; Figure 2F) and dp/dt (341.700 ± 71.830; 
Figure 2G) were significantly suppressed in hearts isolated from Control rats compared to their 
pre-ischemic state (AFpre: 23.170 ± 4.554; COpre: 43.500 ± 5.054; dp/dtpre : 1650 ± 96.120; AoPpre: 
93.330 ± 9.482 and SVpre: 0.268 ± 0.021). In contrast, only the post-ischemic AF (2.400 ± 0.778), AoP 
(68.800 ± 3.952) and dp/dt (558.300 ± 55.630) showed significant reduction in MSH treated group 
compared to pre-ischemic values (AFpre: 22.800 ± 2.480; dp/dtpre: 1133 ± 127.200; AoPpre: 98.200 ± 
2.760). In other words, despite the fact that there were few remarkable differences between the two 
groups at parallel time points of measurement, in MSH group post-ischemic CO (19.400 ± 2.849) and 
SV (0.128 ± 0.025) values did not reach statistical significance in reduction compared to their 
pre-ischemic state (COpre: 42.000 ± 4.195; SVpre: 0.249 ± 0.021). No significance was found in 
coronary flow and heart rate values, neither between groups, nor between different time points of 
the same group (Figure 2B,C). 
2.5. Enhancement of Cardiomyocyte Contractile Performance after Alpha-MSH Treatment 
Active tension-pCa relationships of LV cardiomyocytes (Figure 3A) apparently showed 
alpha-MSH-induced changes in cellular mechanical performance of ZDF rats. LV cardiomyocytes 
from ZDF animals after vs. without alpha-MSH treatment had a trend towards higher active tension 
(at pCa 5.6: 31.04 ± 3.44 kN/m2 vs. 23.38 ± 2.46 k /m2, p = 0.08; at pCa 5.8: 25.50 ± 3.43 kN/m2 vs. 18.13 
± 2.15 kN/m2, p = 0.08). Normalized force-pCa relationships of LV cardiomyocytes (Figure 3B) from 
treated vs. Control ZDF rats showed similar Ca2+ sensitivity (pCa50: 5.87 ± 0.03 vs. 5.82 ± 0.02; Figure 
3C), but significantly higher Hill coefficient (nHill: 2.87 ± 0.19 vs. 2.17 ± 0.08; Figure 3D) as indicative 
for better myofilament co-operation in the alpha-MSH-treated group. 
 
Figure 3. Enhanced contractile performance of left ventricular cardiomyocytes following alpha-MSH 
treatment. (A) Active tension-pCa relationships; (B) Normalized force-pCa relationships; (C) 
Half-value of Ca2+ sensitivity curves on Panel B indicates myofilament Ca2+ sensitivity (pCa50); (D) 
Steepness of Ca2+ sensitivity curves on Panel B indicates myofilament co-operation as Hill coefficient 
(nHill). Data are given as mean ± SEM, whereas n = 12 cardiomyocytes (from 3 to 4 hearts)/groups. P 
values were calculated by unpaired t-test and shown when p < 0.05. 
  
Figure 3. Enhanced contractile performance of left ventricular cardiomyocytes following alpha-MSH
treatm nt. (A) Active te sion-pCa relationships; (B) Normalized force-pCa rela ionships; (C) Half-value
of Ca2+ sensitivity urves on Panel B indicates myofilament Ca2+ sensitivity (pCa50); (D) Steepness
of Ca2+ sensitivity curves on Panel B i dicat s myofil ment c -operation as Hill coefficient (nHill).
Data are given as m an ± SEM, whereas n = 12 cardiomyoc tes (from 3 to 4 he rts)/groups. P valu s
were calcul ted by u paired t-test and shown when p < 0.05.
2.6. Vascular Status Brain Arteries
Significantly higher hyperpolarization induced relaxation in the ZDF Control group compared
to alpha-MSH treated group (5.52 ± 0.56 mN in ZDF vs. 2.73 ± 1.05 mN in alpha-MSH treated ZDF
p < 0.05 at 16 mM KCl) although no difference in the maximal contractile force evoked by 66 mM KCl
(1.06 ± 0.466 mN in the Control group vs. 2.49 ± 0.77 mN in the alpha-MSH treated group) was seen
during contractile force measurement experiments (Figure 4A).
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Figure 4. Vascular status of brain arteries—contractile force measurements. (A) KCl evoked responses;
(B) Serotonin (5HT) evoked responses; (C) Angiotensin II evoked responses. * p < 0.05, all data are
presented as mean ± SD.
No difference was found between the 5HT responses of the two groups (7.31 ± 0.85 mN in
Control group vs. 7.95 ± 1.51 mN in the alpha-MSH treated group for the maximal 10 µM dose of 5HT;
Figure 4B).
There was also no difference in the ATII evoked contractions between the two groups
(1.99 ± 0.55 mN in the Control group vs. 1.53 ± 0.188 mN in the alpha-MSH treated group for
the maximal 100 µM dose of ATII; Figure 4C).
2.7. NADPH Oxidase Activity
NADPH oxidase activities of left ventricle samples did not differ significantly in the α-MSH
treated and untreated Control groups (Figure 5).
Molecules 2017, 22, 1702 7 of 18 
 
2.6. Vascular Status Brain Arteries 
Significantly higher hyperpolarization induced relaxation in the ZDF Control group compared to 
alpha-MSH treated group (5.52 ± 0.56 mN in ZDF vs. 2.73 ± 1.05 mN in alpha-MSH treated ZDF p < 0.05 
at 16 mM KCl) although no difference in the maximal contractile force evoked by 66 mM KCl (1.06 ± 
0.466 mN in the Control group vs. 2.49 ± 0.77 mN in the alpha-MSH treated group) was seen during 
contractile force measurement experiments (Figure 4A). 
 
Figure 4. Vascular status of b ain arteries—contractile force ea urements. (A) KCl evoked 
responses; (B) Serotonin (5HT) evoked responses; (C) Angiotensin II evok d responses. * p < 0.05, all 
data are presented as mean ± SD. 
No difference was found between the 5HT responses of the two groups (7.31 ± 0.85 mN in 
Control group vs. 7.95 ± 1.51 mN in the alpha-MSH treated group for the maximal 10 μM dose of 
5HT; Figure 4B). 
There was also no difference in the ATII evoked contractions between the two groups (1.99 ± 
0.55 mN in the Control group vs. 1.53 ± 0.188 mN in the alpha-MSH treated group for the maximal 
100 μM dose of ATII; Figure 4C). 
2.7. NADPH Oxidase Activity 
NADPH oxidase activities of left ventricle samples did not differ significantly in the α-MSH 
treated and untreated Control groups (Figure 5). 
 
Figure 5. Effects of α-MSH treatment on NADPH stimulated NADPH oxidase activities of left 
ventricular tissue homogenates. Data are expressed as mean ± SEM (Studetn’s t-test). Samples were 
measured in duplicates, and the average of the averages are shown. CPM, Count Per Minute; 
NADPH, Nicotine adenine dinucleotide phosphate; α-MSH, α-Melanocyte-stimulating hormone 
Figure 5. Ef ects of α- SH treatment on NADPH stimulated NADPH oxidase activities of left
ventricular tis ue ho ogenates. Data are expressed as ean ± SE (Studen ’s t-test). Sa ples were
easured in duplicates, and the av rage of the averages a e shown. CPM, Count Per Mi ute; NADPH,
icotine adenine dinucleotide phosphat ; α-MSH, α-Melanocyte-stimulating hormone.
3. Discussion
Alpha-MSH (α-MSH), a neuropeptide derivative of proopiomelanocortin, is a melanotropin
(melanocyte-stimulating hormone) secreted to bind with melanocortin receptors, with resulting
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downstream physiologic effects, principally food-intake regulation, with resulting weight loss and
prevention of obesity—and corollary reduction of diabetes risk [37].
Results of the present investigation included an observation that alpha-MSH-treated animals
exhibited lower weight gain than vehicle-treated control rats, however this difference was
non-significant for the sample size studied. This outcome notwithstanding, significant differences
were noted between alpha-MSH-treated versus control animals in the ratios of left ventricle to whole
body mass at the end of the experiment (Table 1). A major implication of this result is that there
was greater thickening in the left ventricular walls of control animals versus those treated with the
hormone. Since this phenomenon, known as ventricular wall hypertrophy, is associated with increased
risk of ischemic heart failure [38,39], treatment with alpha-MSH was for these experiments, assessed
as beneficial—with potential for human clinical applications.
At the time of writing, few published descriptions are available that describe correlation between
alpha-MSH and blood cholesterol levels. Moreover, results shown here, suggest that alpha-MSH
does not directly modulate serum total cholesterol, high density lipoprotein (HDL), or triglycerides.
Nevertheless, reports by other investigators demonstrate effects of the hormone on cholesterol-related
pathologic processes. For example, investigators in Finland showed that engagement of type 1
and 3 melanocortin receptors—to which alpha-MSH may bind, protects against atherosclerotic
plaque-formation, although the mechanism of this process remains obscure[39]. It has also been shown
that constitutive cholesterol-dependent endocytosis of the melanocortin-4 receptor (MC4R) is essential
for maintenance of receptor responsiveness to alpha-MSH [40]. The above results are intriguing but do
not definitively establish existence of direct functional relationships between cholesterol-homeostasis
and alpha-MSH activity. It is further worth noting that the ZDF rat model is considered to be
non-optimal for evaluation of hypercholesterolemic pathology.
Previous studies have demonstrated the central regulatory role of alpha-MSH in food intake, fat
and glucose homeostasis, it reduces appetite and enhances energy expenditure [41,42]. It has also
been shown that alpha-MSH is also capable of limiting fat deposition by increasing lipolysis [43,44].
Related studies showed that chronic central and acute peripheral administration of an alpha-MSH
analogue, decreased food intake and body weight and limited insulin resistance in a high-fat diet
induced obesity mouse study [45]. Investigators conducting the above study further demonstrated
a waning of the hormone’s appetite-reducing capacity. This effect was speculated to occur as
a consequence of either receptor desensibilisation, or the superimposition of one or two adaptive
responses. The present study is the first to evaluate the effect of peripherally administered (via
an osmotic pump) alpha-MSH on blood glucose levels in a ZDF rat model of diabetes and obesity.
The experimental design parameters used here, were established to enable parallel, comparative
studies with previous work, using a variety of models. Data trends observed here, exhibited patterns
similar to work by related investigations, albeit without statistical significance (Figure 1).
Echocardiographic outcomes shown in Table 2, reveal the protective effects of long-term
alpha-MSH treatment on cardiovascular systolic and diastolic function. This result is relevant
to previous work by authors of the present report, in which echocardiographic parameters were
monitored using single acute administration of alpha-MSH doses (10, 100 and 250 µg/kg), with
resulting significant enhancement of systolic function (EF, FS) [46]. In the present study, the chronic
alpha-MSH treatment engendered a similar pattern. Specifically, in animals receiving the hormone,
fractional shortening, ejection fraction, stroke volume and cardiac output values were significantly
elevated in comparison with control animals (FS: 32.33± 0.421% vs. 36.83± 0.703%; EF: 66.50± 0.067%
vs. 72.00 ± 0.774%, SV: 0.41 ± 0.046 mL vs. 0.58 ± 0.030 mL, CO: 77.55 ± 7.763 mL/min vs.
112.30 ± 6.110 mL/min), respectively. Left ventricular outflow tract (LVOT) values are also increased
in treated group, demonstrating direct correlation with elevated EF, FS, SV and CO as indicators
of systolic function (Table 2). These outcomes should be considered in the context of observations
that melanocortin analogues correlate with mild sympathetic activation in the cardiovascular system,
including increased heart rate and blood pressure. However, in the present study the systolic and
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diastolic values measured by in vivo non-invasive tail-cuff blood pressure system, which utilized
Volume Pressure Recording (VPR) sensor technology, showed non-significant trends for increase in
these values (Table 1). A possible explanation for this result, may be that long acting administration of
alpha-MSH, is attenuated in the diseased model—but may nevertheless prove useful future strategies
for prevention and therapy of obesity-related syndromes.
Previous investigations have shown that typically alpha-MSH does not affect blood pressure or
may only slightly elevate it [34,46]. Moreover, other effects of the hormone on other echocardiographic
outcomes shown here, bear consideration. For example, increasing left atrial aortic root ratio (LA/Ao)
value indicates means left atrial dilation. Here, alpha-MSH treatment decreased these values, although,
both remained in healthy range. MV Deceleration Time (ms), a powerful prognostic marker of LV
remodelling and diastolic dysfunction was also considered. Influences that affect MV alters the
relationship between early and late filling (E- and A-wave), along with how rapidly flow velocity
declines in early diastole (E-wave deceleration time = DT)—and time interval for ventricular filling
following relaxation of the ventricle—a value termed: length of the isovolumetric relaxation time
(IVRT). α-MSH osmotic pump treatment was observed to significantly improve the diabetes-induced
diastolic dysfunction. MV Deceleration Time: 66.67 ± 3.201 vs. 85.50 ± 5.258 ms, and IVRT: 58 ± 1.826
vs. 43 ± 1.125 ms standards were enhanced for hormone-treated animals in comparison with control
rats. Other experiments in the present study considered mitral annular plane systolic excursion
(MAPSE) also known as left atrioventricular plane displacement (AVPD). Mitral annulus excursion
(MAE) or mitral ring displacement is an M-mode-derived echocardiographic marker of LV longitudinal
function [47–49]. In previous studies reduced MAPSE has been shown to correlate with age, and
LV function in patients with myocardial infarction, heart failure and atrial fibrillation [50–53] and
to be more sensitive than conventional echocardiographic markers in detecting abnormalities of LV
systolic function at an early stage [7,18]. MAPSE is also known to be prognostic parameter for major
cardiac events and mortality in patients with cardiovascular disease [54]. Another measure of heart
function considered here, the myocardial performance index (MPI) is an easily performable, recordable
and reproducible parameter that may be determined by flow Doppler. In humans, MPI values are
independent of arterial pressure, heart rate, ventricular geometry, atrioventricular valve regurgitation,
afterload, and preload in patients who are in a supine position. MPI as a single prognostic variable,
may be used for assessment of diabetic cardiac dysfunction [55]. The present investigation showed
that long-term alpha-MSH treatment significantly improved both parameters in our present study;
MAPSE: 1.602 ± 0.045 vs. 2.268 ± 0.010 mm, MPI: 0.491 ± 0.014 vs. 0.392 ± 0.01.
Evaluation of cardiac functions in Langendorff-mounted isolated working hearts shown
in Figure 2 revealed significantly increased pre-ischemic pressure change rate (dp/dt) value in
MSH group compared to untreated Control group. Also, as shown in Figure 2 ischemic-reperfusion
injury-associated decreases in AF, dp/dt, AoP versus pre-ischemic values were observed in both groups
by the end of recovery. Despite the fact that nearly all outcome parameters decreased after 120 min of
reperfusion, elevated AF and SV were measured at the 30 min recovery time point in the α-MSH-treated
group, relative to control animals. Moreover, post-ischemic CO and SV values in animals receiving the
hormone did not reach statistical significance in magnitude of suppression, versus their pre-ischemic
state. These findings are consistent with previous studies by the authors, in which alpha-MSH
treatment significantly inhibited the extent of ischemia/reperfusion-induced infarct zones, increased
the magnitude of CO and SV, therefore provides additional evidence of the range of cardio-protective
effects mediated by the hormone [46]. These outcomes notwithstanding, little investigative work has
addressed this issue at the time of the present writing and awaits further exploration. Significantly,
related studies have demonstrated that melanocyte-stimulating hormone administered before ischemia,
increases the effectiveness of post-ischemic recovery of function [46,56,57]. Further, recent work
by authors of the present report and others, demonstrate that melanocortins protect against tissue
damage in response to prolonged myocardial ischemia/reperfusion via activation of pro-survival HO-1
protein, JAK/ERK/STAT signalling and decreased expression of the pro-inflammatory mediator TNF-α
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and pro-inflammatory/pro-apoptotic factor pJNK and also by vagus nerve-mediated cholinergic
anti-inflammatory pathway [46,57,58]. Analysis of results of cardiomyocyte contractile performance
data, showed improved actin-myosin co-operation and strong trends toward a higher active
tension—suggesting improved cardiomyocyte mechanical performance that may contribute to the
beneficial effects of alpha-MSH on global cardiac contractility (Figure 5). In contrast, it appears that
MSH had no effect on Ca2+ sensitivity of the contractile apparatus. Moreover, it was also noted that
the effects of hormone treatment on cerebral vascular smooth muscle, produced no deleterious effects.
Specifically, the treatment did not alter values for KCl, serotonin, or responses evoked by angiotensin
II (Figure 4)—indicating an apparent lack of vascular response to α-MSH stimulation (Figure 3).
In accordance with previous studies, one of the major hypotheses which may account for the
protective effect of the hormone was its immunomodulatory, anti-inflammatory and antioxidant
properties [59,60]. These phenomena were a major rationale for aspects of experimental design used
in the present study, involving assessment of NADPH oxidase enzyme activity, outcomes of which
are shown in Figure 4. Nevertheless, a limitation of the current study is that we only investigated the
hormone’s antioxidant capacity by measuring NADPH oxidase activity. Other possible mechanisms
are under intensive research to clarify beneficial effects of the hormone.
4. Materials and Methods
4.1. Animal Model and Chemicals
Male Zucker Diabetic Fatty (ZDF-Leprfa) rats weighing 300–350 g (at age of 10 weeks, n = 12) were
provided by Charles River International Ltd. (Wilmington, MA, USA). Animals were housed under
a 12–12 h light-dark cycle and were kept on Purina 5008 special chow (LabDiet, St. Louis, MO, USA)
and tap water, as recommended by the distributor. All experimental protocols were approved by the
local Ethics Committee of University of Debrecen and the animals received humane care in accordance
with the “Principles of Laboratory Animal Care” by EU Directive 2010/63/EU. A 4-week adaptation
period was provided to animals before the start point of the study. Alpha-MSH and all other chemicals
used for buffer solutions were obtained from Sigma-Aldrich Co. (Budapest, Hungary).
4.2. Study Design
After recording baseline data (n = 12), including weight, OGT test and echocardiographic
recordings, rats were randomly divided into 2 subgroups as follows: untreated animals (Control;
n = 6) receiving vehicle (saline solution), and animals (MSH; n = 6) receiving alpha-MSH solution,
both subcutaneously administered by mini-osmotic pumps (as detailed in Section 4.3), for 6 weeks.
A limitation of this current report is that we do not present data about lean control animals.
Alpha-MSH concentration was adjusted to 4.8 mg/mL, and the pump delivered 0.15 µL/h (0.72 µg
alpha-MSH in each hour). After six weeks, study was terminated, endpoint data (weight, OGTT,
echocardiography, serum parameters and blood pressure) was recorded, and rats were sacrificed by
thoracotomy under deep anaesthesia by ketamine/xylazine combination (CALYPSOL® (ketamine),
Richter Gedeon Plc., Budapest, Hungary; NERFASIN® (xylazine) Le Vet. Pharma BV, Oudewater,
The Netherlands). Hearts and basilar arteries were excised. Isolated working heart method was carried
out, and cardiac tissue samples were rapidly frozen for NADPH oxidase activity and for myocyte force
measurements. Basilar arteries were subjected to contractile force studies.
4.3. Osmotic Pump Implant Surgery
Alzet® osmotic mini-pumps (Durect Corp., Cupertino, CA, USA) were surgically implanted
into a 1 cm opening in the nape skin of ZDF rats under ketamine/xylazine (100/5 mg/kg) deep
anaesthesia. Before implantation, the pumps were primed by injecting them with alpha-MSH solution
(200 µL solution at the concentration of 4.8 mg/mL) and placing them into 37 ◦C physiological SAL
for a minimum of 4 h [61]. Following insertion of the mini-pumps, the skin was closed with surgical
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sutures, and the wound was disinfected with Betadine® solution (Egis Pharmaceuticals PLC, Budapest,
Hungary). Surgery time was 10–15 min, and the rats received postoperative care. The pump provided
continuous administration of 0.15 µL content per hour. The mini-pumps of the control group were
filled with physiological SAL and were implanted with the same methods.
4.4. Oral Glucose Tolerance Test (OGTT)
OGTT for ZDF rats was performed according to the standard method. Briefly, all animals were
selected for OGT test at baseline and at the endpoint, after starving at water for 12 h. 3 g/kg glucose was
administered in 1 g/mL solution for each animal via gavage technique [62]. The serum blood glucose
levels were obtained by pricking the tail vein and using glucometer (Accu-chek, Roche Diagnostic,
Indianapolis, IN, USA) at time 0 (baseline), 30, 60, 90, 120 and 180 min.
4.5. Blood Pressure Measurement of Conscious Rats
At the endpoint, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were
measured by a non-invasive tail-cuff blood pressure system utilizes Volume Pressure Recording
(VPR) sensor technology, (CODA™ Surgical Monitor, Kent Scientific Corp., Torrington, CT, USA).
Measurements were obtained in conscious rats restrained in a thermal plastic chamber as described
elsewhere [63]. Five consecutive recordings were evaluated in each animal to ensure results.
4.6. Analysis of Serum Parameters
At the endpoint of the treatment, after 14-h fasting, rat blood samples were collected from the
tail vein in EDTA-K2 evacuated tubes (BD Vacutainer, Franklin Lakes, NJ, USA). The samples were
collected and processed aseptically to minimize haemolytic activity. Serum glucose, cholesterol and
triglyceride were detected by Department of Laboratory Medicine at the University of Debrecen.
4.7. Echocardiographic Studies
Echocardiographic imaging was carried out according the protocol detailed previously by the
authors [35,36]. Briefly, measurements were performed under intramuscular anaesthesia (ketamine
50 mg/kg, xylazine 5 mg/kg) at the baseline and at the endpoint of the study. The chest hair was shaved
and the animals were positioned in a dorsal position. Data acquisition was performed using a Vivid E9
sonograph (GE Healthcare, New York, NY, USA), with an i13L linear array probe at 14 MHz with high
temporal and spatial resolution [64–67]. Complete 2-dimensional, M-mode (at papillary muscle levels),
Doppler (PW), and tissue Doppler (TVI) echocardiograms were acquired and digitally stored for
further analysis as recommended by the American Society of Echocardiography. ECG was continously
monitored during echocardiographic examinations in all cases. Obtained M-mode, Doppler and tissue
Doppler parameters included the followings: aortic root diameter (Ao), left atrial diameter (LA),
interventricular septum thickness in diastole and systole (IVSs, IVSd), left ventricular internal diameter
at end-diastole (LVIDd) and end-systole (LVIDs), left ventricular ejection fraction (EF), fractional
shortening (FS), stroke volume (SV, calculated), cardiac output (CO, calculated), heart rate (HR), mitral
annular peak systolic excursion (MAPSE), left ventricular peak E and peak A waves (mitral early
and late filling velocities), the E to A ratio (E/A), ejection time (ET), isovolumic contraction- and
relaxation time (IVCT and IVRT), myocardial performance index (MPI or Tei-index), lateral e’ and
a’ wave velocities, lateral e’/a’ ratio, E/e’ ratio. Left ventricular outflow tract (LVOT) maximal and
mean velocity and pressure parameters: LVOT Vmax, Vmean, LVOT maxPG and meanPG. LV mass
was calculated by echocardiography, using the following formula: LV Mass (g) = 0.8{1.04[([LVIDd +
IVSd + PWd]3 − LVIDd3)]} + 0.6; where LVIDd is the diameter of the left ventricle in end-diastole;
IVSd is thickness of the interventricular septum in diastole; PWd is the thickness of the posterior
wall in diastole. Acquired images were analysed using the EchoPAC PC software (GE Healthcare,
New York, NY, USA) by a blinded reader.
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4.8. Isolated Working Heart Preparation
All animals (n = 12) were anesthetized with ketamine/xylazine (100/5 mg/kg, i.m.). A bolus of
heparin was administered (1000 U/kg, intravenously) 20 min before the thoracotomy, to avoid the
thrombosis. Thoracotomies were performed on each animal; the hearts were excised and placed into
ice-cold modified Krebs-Henseleit perfusion buffer (mKH buffer). The aortas were then cannulated,
and hearts were perfused according to Langendorff method for a 5-min washout period at a constant
perfusion pressure equivalent to 100 cm of water (10 kPa). The perfusate was filtered (5 µm pore
size) in-line and had the following composition: NaCl, 118 mmol/L; NaHCO3, 25 mmol/L; KCl,
4.8 mmol/L; CaCl2, 1.8 mmol/L; Mg2SO4, 1.2 mmol/L; KH2PO4, 1.2 mmol/L; and glucose, 11 mmol/L.
A dual-headed peristaltic pump controlled the rate of perfusion of mKH buffer. Following retrograde
perfusion, working-mode perfusion was performed cardiac function was assessed as described
previously [68]. Heart rate (HR), aortic pressure (AoP), left ventricular developed pressure (LVDP)
were recorded using a PowerLab (ADInstruments) aortic flow (AF) and coronary flow (CF) were
measured by using flowmeter, stroke volume (SV) and cardiac output (CO) were further derived from
these measures [69–71]. Hearts were then maintained to 30 min of global ischemia. After ischemia,
hearts were perfused for 15 min in Langendorff mode and then converted to working heart mode for
105 min. The above-mentioned parameters were measured and recorded during the reperfusion at
the 30, 60, 90 and 120 min. Immediately after 120 min reperfusion small myocardial biopsies from LV
heart tissue were removed and frozen for further analysis [72].
4.9. Force Measurements of Isolated Cardiomyocytes
Contractile function of skinned left ventricular (LV) cardiomyocytes (n = 12 per group) from
isolated working hearts (n = 3–4) after the protocol of ischemia/reperfusion (I/R) was measured as it
described previously [73]. Briefly, deep-frozen (−80 ◦C) tissue samples were mechanically disrupted
and demembranated by 0.5% Triton X-100 detergent for 5 min in isolating solution (MgCl2: 1.0 mM; KCl:
100.0 mM; EGTA: 2.0 mM; ATP: 4.0 mM; imidazole: 10.0 mM; pH 7.0) at 4 ◦C. Each subjected cell was
attached with silicone adhesive at one end to a stainless steel insect needle connecting to a high-speed
length controller (Aurora Scientific Inc., Aurora, ON, Canada), while at the other end to a stainless
steel insect needle connecting to a sensitive force transducer (SensoNor AS, Horten, Norway) at 15 ◦C.
Subsequent cardiomyocyte isometric force generation was recorded at sarcomere length of 2.3 µm
and analysed by LabVIEW software (National Instruments Corp., Austin, TX, USA). Ca2+-dependent
force production of a single cardiac cell was induced by transferring the preparation from relaxing
(BES: 10.0 mM; KCl: 37.11 mM; MgCl2: 6.41 mM; EGTA: 7.0 mM; ATP: 6.94 mM; creatine phosphate:
15.0 mM; pH7.2) to activating solutions (same composition as relaxing solution aside from containing
Ca2+-EGTA instead of EGTA). Ca2+ concentrations were indicated as −log10[Ca2+] units (pCa).
Protease inhibitors were added to all solutions freshly: phenylmethylsulfonyl fluoride: 0.5 mM;
leupeptin: 40 µM and E-64: 10 µM. All chemicals were purchased from Sigma-Aldrich Corp. (St. Louis,
MO, USA). Cardiomyocyte Ca2+-activated force generation was registered by using maximal activating
solution (pCa 4.75) and activating solutions with different pCa (5.4–7.0). Submaximal forces were
normalized to maximal force and fitted to a modified Hill equation in Origin 6.0 analysis program
(OriginLab Corp., Northampton, MA, USA). The pCa value for the half-maximal contraction indicated
by pCa50 defines per se the Ca2+ sensitivity of force generation of the contractile machinery, while
the steepness of the Ca2+ sensitivity curve expressed as a coefficient (nHill) reflects the co-operation
between the myofilaments. Original active forces were normalized to myocyte cross-sectional area
indicating active tension (expressed in kN/mCa2). Statistical analysis was performed by GraphPad
Prism 5.02 software (GraphPad Software Inc., La Jolla, CA, USA). Data were compared with unpaired
Student’s t-test.
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4.10. Arterial Contractile Force Measurement
During the isolated heart experiments, after thoracotomies performed under ketamine/xylazine
anaesthesia, the brain was removed and placed into a silicone containing petri dish, filled with 0–4 ◦C
Krebs solution (composition in mmol: 110 NaCl, 5.0 KCl, 1.0 MgSO4, 1.0 KH2PO4, 5.0 glucose and
24.0 NaHCO3, obtained from Sigma-Aldrich, St. Louis, MO, USA). The solution was equilibrated
previously with a gaseous mixture of 5% CO2, 10% O2 and 85% N2 at pH 7.4. Basilar arteries were
isolated with microsurgical tools (Fine Science Tools GmbH, Heidelberg, Germany). The arteries were
equally cut into 4 mm long rings, which were then mounted in an isometric contraction measurement
system (DMT-510, Danish Myotechnology, Aarhus, Denmark). The Ca2+-free Krebs solution was
changed to Ca2+-containing one (composition in mM: 110 NaCl, 2.5 CaCl2, 5.0 KCl, 1.0 MgSO4,
1.0 KH2PO4, 5.0 glucose and 24.0 NaHCO3, obtained from Sigma-Aldrich, St. Louis, MO, USA).
Before every experiment, a normalization protocol was performed, by stretching the preparations
with 1.5 mN force, which was increasing evenly every 15 s until the calculated intraluminar pressure
reached 13.4 kPa. The experiments were then performed at this stretch level. Contractile responses for
KCl (6–66 mM), serotonine (1 nM–10 µM) and angiotensin II (1 nM–100 µM) have been recorded.
4.11. NADPH Oxidase Activity Measurement
NADPH oxidase-derived superoxide production was measured using lucigenin-enhanced
chemiluminescence, as described previously [74,75]. Left ventricular (LV) samples were snap frozen
immediately after termination of ex vivo perfusion experiments and were stored on −70 ◦C until
subsequent analyses. Approximately 100 mg (wet tissue) of LV heart samples (n = 4 from both α-MSH
treated and untreated) were homogenized (Pro200 homogenizer, Proscientific, Oxford, CT, USA) in
10 volumes of ice cold 1× Ca2+-free Dulbecco’s Phosphate Bufferred Saline (Gibco®, Thermo Fisher,
Waltham, MA, USA) containing 40 µM leupeptin, and 5 µM E64 protease inhibitors. After centrifuging,
the pellet was discarded and Bicinchoninic Acid Assay was used to determine protein concentration in
the supernatant using bovine serum albumin (BSA) as a standard (all chemicals from Sigma-Aldrich,
St. Louis, MO, USA). Protein concentrations were ~20 mg/mL. The reaction mixture for the
measurement of NADPH oxidase enzyme activity contained 50 µL heart homogenate in a buffer
of Krebs- (4-(2-hydroxy-ethyl)-1-piperazineethanesulfonic acid (HEPES) (110 mM NaCl, 5 mM KCl, 1
mM MgSO4, 1 mM KH2PO4, 5 mM glucose, 24 mM NaHCO3, 20 mM HEPES, 50 µM lucigenin). The
scintillation tubes went through dark adaptation, and basal luminescence of samples were recorded via
PerkinElmer Tricarb 2800 tr liquid scintillation counter (PerkinElmer, Waltham, MA, USA). Enzymatic
reaction was stimulated by adding 100 µM NADPH to the reaction mixture. Luminescence was
recorded directly after for 2 min. Differences between basal and stimulated luminescence were
calculated and values were normalized to protein concentration.
4.12. Statistical Analyses
All data are presented as the average magnitudes of each outcome in a group ± standard
error of the mean (SEM). The D’Agostino & Pearson omnibus normality test was used to estimate
Gaussian distribution. Statistical analysis was performed using one-way analysis of variance (ANOVA)
with Bonferroni post-testing (when normality test was passed) or by Kruskal-Wallis test with Dunn’s
post-testing (if the normality test was not passed). Student’s t-test was used to determine of significance
in the case of comparing significance of two groups. Statistical analyses were conducted using
GraphPad Prism software for Windows, version 5.01 (GraphPad Software Inc., La Jolla, CA, USA).
Probability values (p) less than 0.05 were considered statistically significant.
5. Conclusions
Long term α-MSH treatment using a mini osmotic pump has significant potential for prevention
of and therapy for diabetes-induced systolic or diastolic dysfunction which is not associated with
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Ca2+ sensitivity and/or vascular status. The study further suggest that ischemia/reperfusion induced
cardiac damages are also attenuated but through mechanisms that appear to occur independently
from the hormone’s antioxidant features.
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